SCHEMBL2149971

SCHEMBL2149971

CSc1ccc(SC(P(=O)(O)O)P(=O)(O)O)cc1

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.66
MMP8 P22894 1/20 0.66
MMP14 P50281 1/20 0.66
MMP1 P03956 1/20 0.46
PLK1 P53350 1/20 0.42
FDPS P14324 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
SLC6A4 P31645 7/20 0.35
NOS3 P29474 2/20 0.35
NOS1 P29475 2/20 0.35
MAOA P21397 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A3 Q01959 1/20 0.34
PTGS2 P35354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26135898 0.98 MMP2 (0.63) MMP2MMP8MMP14MMP1PLK1
SCHEMBL2150897 0.98 MMP2 (0.63) MMP2MMP8MMP14MMP1PLK1
SCHEMBL2150903 0.87 MMP2 (0.51) MMP2MMP8MMP14MMP1PLK1
SCHEMBL8589347 0.83 MMP2 (0.66) MMP2MMP8MMP14MMP1FDPS
SCHEMBL10788079 0.83 MMP8 (0.66) MMP2MMP8MMP14MMP1FDPS
SCHEMBL29406152 0.82 MMP1 (0.69) MMP2MMP8MMP14MMP1PLK1
SCHEMBL8588507 0.81 MMP2 (0.49) MMP2MMP8MMP14FDPSALDH1A1
Tiludronic Acid SCHEMBL18988 0.79 MMP2 (1.00) MMP2MMP8MMP14MMP1FDPS
SCHEMBL7177633 0.79 MMP2 (0.59) MMP2MMP8MMP14MMP1FDPS
SCHEMBL8588143 0.79 MMP2 (0.59) MMP2MMP8MMP14MMP1FDPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213597-A1 AGENT FOR INDUCING PROLIFERATION OR DIFFERENTIATION OF CHONDROCYTE TOHOKU UNIVERSITY (JP) 2025-07-03 US claimed
EP-4501331-A1 AGENT FOR INDUCING PROLIFERATION OR DIFFERENTIATION OF CHONDROCYTE Tohoku University (JP) 2025-02-05 EP claimed
CN-119212712-A Proliferation or differentiation inducer for chondrocytes 国立大学法人东北大学 2024-12-27 CN claimed
WO-2023190685-A1 AGENT FOR INDUCING PROLIFERATION OR DIFFERENTIATION OF CHONDROCYTE 国立大学法人東北大学 2023-10-05 WO claimed
EP-2340841-B1 OSTEOGENESIS PROMOTER COMPRISING [4-(METHYLTHIO)PHENYLTHIO]METHANEBISPHOSPHONIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT UNIV TOHOKU (JP) 2016-11-09 EP claimed
US-20110230447-A1 OSTEOGENESIS PROMOTER COMPRISING [4-(METHYLTHIO)PHENYLTHIO]METHANEBISPHOSPHONIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT TOHOKU UNIVERSITY (JP) 2011-09-22 US claimed
EP-2340841-A1 OSTEOGENESIS PROMOTER COMPRISING [4-(METHYLTHIO)PHENYLTHIO]METHANEBISPHOSPHONIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT Tohoku University (JP) 2011-07-06 EP claimed
US-6579860-B1 Thrombocytosis inhibitor, methanebisphosphonic acid derivatives TORAY INDUSTRIES, INC. (JP) 2003-06-17 US claimed
US-6555529-B1 Administering (4-methylthiophenylthio)methane-1,1-bisphosphonic acid for treatment of bone marrow disorders such as inflammatory disease, myeloma, anemia, and leukemia TORAY INDUSTRIES, INC. (JP) 2003-04-29 US claimed
EP-0998934-A1 REMEDIES FOR INTRAMEDULLARY DISEASES TORAY INDUSTRIES, INC. (JP) 2000-05-10 EP claimed
US-20250213597-A1 AGENT FOR INDUCING PROLIFERATION OR DIFFERENTIATION OF CHONDROCYTE TOHOKU UNIVERSITY (JP) 2025-07-03 US disclosed
EP-4501331-A1 AGENT FOR INDUCING PROLIFERATION OR DIFFERENTIATION OF CHONDROCYTE Tohoku University (JP) 2025-02-05 EP disclosed
CN-119212712-A Proliferation or differentiation inducer for chondrocytes 国立大学法人东北大学 2024-12-27 CN disclosed
WO-2024247839-A1 ANTIOXIDANT 風間 順一郎 2024-12-05 WO disclosed
WO-2023190685-A1 AGENT FOR INDUCING PROLIFERATION OR DIFFERENTIATION OF CHONDROCYTE 国立大学法人東北大学 2023-10-05 WO disclosed
EP-0594857-B1 METHANEDIPHOSPHONIC ACID DERIVATIVE, PRODUCTION THEREOF AND MEDICINAL USE THEREOF TORAY INDUSTRIES (JP) 1998-04-29 EP disclosed
US-5683992-A TREATMENT OF RHEUMATISM, BONE DISORDERS, ANTIINFLAMMATORY, SUPPRESSION OF INTERLEUKIN-1, ANTIOXIDANT, TREATMENT OF AUTOIMMUNE DISEASES TORAY INDUSTRIES, INC. (JP) 1997-11-04 US disclosed
EP-0725070-A1 PROCESS FOR PRODUCING METHANEDIPHOSPHONIC ACID COMPOUND TORAY INDUSTRIES, INC. (JP) 1996-08-07 EP disclosed
US-5527940-A SUPPRESSES INTERLEUKIN-1 AND BONE DESTRUCTION DURING OSTEOPOROSIS; ANTIINFLAMMATORY AGENTS TORAY INDUSTRIES, INC. (JP) 1996-06-18 US disclosed
EP-0594857-A1 METHANEDIPHOSPHONIC ACID DERIVATIVE, PRODUCTION THEREOF AND MEDICINAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 1994-05-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213597-A1 AGENT FOR INDUCING PROLIFERATION OR DIFFERENTIATION OF CHONDROCYTE MKI67, STAT3, FGF1 MMP2 177/4885MMP8 305/4885MMP14 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.